Amendment: SEC Form 6-K/A filed by Ascentage Pharma Group International

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K/A

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of April 2025

Commission File Number: 002-023311

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On April 23, 2025, Ascentage Pharma Group International issued a press release entitled, “Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin. A copy of the announcement is furnished as Exhibit 99.1 to this Report.

In addition, on April 24, 2025, the Company issued a Hong Kong Stock Exchange voluntary announcement entitled, “ASCENTAGE PHARMA TO PRESENT DATA FROM TWO CLINICAL STUDIES AT 2025 ASCO ANNUAL MEETING, INCLUDING ORAL PRESENTATION ON LISAFTOCLAX”. A copy of the announcement is furnished as Exhibit 99.2 to this Report.

INDEX TO EXHIBITS

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

3